The Administration and Biostatistics Core is designed to provide two main services. First, the Core will oversee all organizational and financial aspects of the application. This will ensure the most efficient and timely utilization ofthe resources, guarantee the collaborative accomplishments ofthe specific aims, provide an optimal degree of interaction among Project Leaders and Core Directors, facilitate programmatic reviews by an internal Steering Committee, and an External Advisory Board (EAB), and spearhead outreach initiatives to distribute research accomplishments generated on the specific aims on a national and international scale. Second, Core A will be responsible for providing a dedicated infrastructure for biostatistics, bioinformatics, data analysis, and quantitative support of all the preclinical studies of prostate cancer therapeutics proposed in the application. As Director of Core A, Dr. Altieri will be responsible for providing a broad-based, transparent and inclusive organizational oversight of the application. This will take advantage of experienced administrative, financial and clerical personnel already in place in the Department of Cancer Biology, who will aid the Principal Investigator in these tasks. Salary support for Dr. Robert Houlihan, Program Administrator, and Ms. Giselle Schultz, Administrative Coordinator, is already provided by the Institution, and no additional funds are requested in the application. As Co-Director of Core A, Drs Chung-Cheng Hsieh will oversee all aspects of biostatistics, bioinformatics, study analysis, sample size determination, and quantitative data interpretation forthe preclinical studies proposed in Projects 1-3 of the application. Core A will equally support all three Projects, and contribute to the mission and services of the two additional Cores contained in the present application.
The services provided by Core A will be essential to integrate the various components of the application in a seamless and coordinated research unit. The biostatistics and bioinformatics support provided by the Core will ensure quantitative conceptualization and proper data analysis of the preclinical studies of network inhibitors contained in the application.
|Wang, Tao; Huang, Jiayi; Vue, Mai et al. (2018) ?v?3 Integrin Mediates Radioresistance of Prostate Cancer Cells Through Regulation of Survivin. Mol Cancer Res :|
|Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228|
|Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35|
|Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072|
|Patel, Sima; Fu, Shuyu; Mastio, Jerome et al. (2018) Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol 19:1236-1247|
|Caino, M Cecilia; Seo, Jae Ho; Wang, Yuan et al. (2017) Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. J Clin Invest 127:3755-3769|
|Altieri, Dario C (2017) Mitochondria on the move: emerging paradigms of organelle trafficking in tumour plasticity and metastasis. Br J Cancer 117:301-305|
|Kumar, Vinit; Donthireddy, Laxminarasimha; Marvel, Douglas et al. (2017) Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell 32:654-668.e5|
|Bryant, Kelly G; Chae, Young Chan; Martinez, Rogelio L et al. (2017) A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget 8:112184-112198|
|Zingiryan, Areg; Farina, Nicholas H; Finstad, Kristiaan H et al. (2017) Dissection of Individual Prostate Lobes in Mouse Models of Prostate Cancer to Obtain High Quality RNA. J Cell Physiol 232:14-8|
Showing the most recent 10 out of 77 publications